Lana Pine

A significantly larger proportion of patients in the dotinurad group met the primary endpoint compared with the febuxostat group at week 24.

The primary endpoint was met by 51% of patients in the high dose group and 43% of patients in the low dose group, compared with only 8% of those receiving placebo.

Reductions in the mean number of tender joints from baseline to month 6 were greater among patients in the treatment groups compared with placebo.

Casey Schlacher discusses the FDA approval of the new weight-based oral solution, RINVOQ LQ (upadacitinib), for treating pediatric patients with arthritis, highlighting its importance for improving patient outcomes and quality of life.

Gerd Burmester, MD, discusses the favorable long-term safety data of upadacitinib treatment across rheumatic diseases.

The study identified 6 key themes highlighting how gout impacts work life, including the severity of physical symptoms, the challenge of physically demanding jobs, and emotional and social experiences.

If approved, zasocitinib could become a leading oral treatment for PsA.

Older children (aged >5 years) with JIA exhibited a 40% to 45% higher point prevalence of active disease at month 12 when compared with younger patients.

Discontinuation was less likely in the prospective Patient Support Program (PSP) group compared with the retrospective non-PSP group.

The rheumatology month in review for June 2024 addresses the critical role of psychological, socioeconomic, and lifestyle factors in the management of rheumatic diseases, particularly rheumatoid arthritis and fibromyalgia.

Diana Girnita, MD, PhD, highlights the crucial role of patient education, the integration of traditional and integrative medicine, and the importance of reliable information for improving health outcomes in chronic conditions.

Shai Efrati, MD, explains how his research aims to address the root cause of fibromyalgia: damaged brain tissue.

The study demonstrated clinical similarity between the proposed biosimilar and the reference products.

Treatment involved repairing the brain tissue using HBOT, which led to significant symptom improvement.

Among all groups, fewer men with rheumatic disease were childless compared with controls.

Treatment with romosozumab or denosumab demonstrated comparable results among patients with either primary osteoporosis or those with rheumatoid arthritis complicated with osteoporosis over a 24-month period.

Patients with the highest daily step count had a 45% lower risk of RA compared with patients in the lowest quarter (< 6818 daily steps).

The incidences of adverse events were comparable between the original and current analyses of patients with moderate to severe RA treated with filgotinib.

Among patients with RA who achieved remission at month 6, between 79.1% and 84.9% were able to sustain remission at month 12.

A greater proportion of patients in the FIL 200 mg group achieved meaningful patient-reported response compared with placebo.

A post hoc analysis of the MIRROR trial suggests comprehensive gout management should aim for remission, incorporating both uric acid lowering and broader symptom improvements.

Data showed a significant reduction in pain for patients with psoriatic arthritis and inadequate response to TNF treated with guselkumab compared with placebo.

Treatment with guselkumab led to rapid, clinically meaningful improvements in disease activity among patients with severe psoriatic arthritis, which were maintained through 2 years.

Results revealed cDAPSA can help providers accurately measure the level of disease activity in patients and predict whether the patient will have radiographic progression.

Daniel Blockmans, MD, PhD, discussed the results of a phase 3 trial that revealed upadacitinib significantly improved outcomes in patients with giant cell arteritis.

Karen Costenbader, MD, discusses the 2 post hoc analyses that demonstrated treatment with belimumab reduces flares and increases response rates among patients with early active SLE.

Karen Costenbader, MD, discusses how early intervention with belimumab in patients with lupus significantly reduces disease flares and prevents irreversible organ damage.

The approval was based on previous data from well-controlled RA studies coupled with findings from a multinational, dose-finding study of pediatric patients with pJIA.

Patients in the active counseling group were more likely to achieve low disease activity or remission.

Participants said the process was easy, convenient, and informed their self-management behaviors.